- Home
- RNAC vs ABEO Comparison
RNAC vs ABEO Comparison
Compare RNAC & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAC
- ABEO
- Stock Information
- Founded
- RNAC 2007
- ABEO 1974
- Country
- RNAC United States
- ABEO United States
- Employees
- RNAC N/A
- ABEO N/A
- Industry
- RNAC Biotechnology: Pharmaceutical Preparations
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- RNAC Health Care
- ABEO Health Care
- Exchange
- RNAC Nasdaq
- ABEO Nasdaq
- Market Cap
- RNAC 276.3M
- ABEO 332.0M
- IPO Year
- RNAC 2016
- ABEO 1980
- Fundamental
- Price
- RNAC $10.05
- ABEO $6.83
- Analyst Decision
- RNAC Strong Buy
- ABEO Strong Buy
- Analyst Count
- RNAC 4
- ABEO 6
- Target Price
- RNAC $40.00
- ABEO $18.17
- AVG Volume (30 Days)
- RNAC 48.4K
- ABEO 702.3K
- Earning Date
- RNAC 08-07-2025
- ABEO 08-14-2025
- Dividend Yield
- RNAC N/A
- ABEO N/A
- EPS Growth
- RNAC N/A
- ABEO N/A
- EPS
- RNAC N/A
- ABEO 0.99
- Revenue
- RNAC $1,026,000.00
- ABEO $400,000.00
- Revenue This Year
- RNAC N/A
- ABEO N/A
- Revenue Next Year
- RNAC N/A
- ABEO $339.63
- P/E Ratio
- RNAC N/A
- ABEO $6.91
- Revenue Growth
- RNAC N/A
- ABEO N/A
- 52 Week Low
- RNAC $8.46
- ABEO $3.93
- 52 Week High
- RNAC $26.50
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- RNAC 34.71
- ABEO 52.71
- Support Level
- RNAC $10.50
- ABEO $6.70
- Resistance Level
- RNAC $11.80
- ABEO $7.15
- Average True Range (ATR)
- RNAC 0.56
- ABEO 0.31
- MACD
- RNAC -0.11
- ABEO -0.02
- Stochastic Oscillator
- RNAC 0.45
- ABEO 46.62
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.